{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055657","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.612874+00:00","generated_at":"2026-06-02T09:42:31.208672+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outset Medical Q1 revenue $28.2M, net loss $(0.78)/share; CTO departs, $3.0M restructuring","bullets":["Revenue $28.2M, down 16% YoY; service revenue up 36% to $7.7M, recurring revenue up 24%.","GAAP net loss $(39.9)M ($(0.78)/share); non-GAAP net loss $(29.3)M ($(0.57)/share).","Total gross margin improved to 29.2% from 19.2% YoY; product margin 38.4% from 25.1%.","FY 2024 guidance reaffirmed: revenue $145-153M, non-GAAP gross margin low-30% range.","CTO Jean-Olivier Racine departs May 17; workforce reduction with $3.0M restructuring charge in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055657","json":"https://secwatch.observer/filing/0000950170-24-055657.json","markdown":"https://secwatch.observer/filing/0000950170-24-055657.md","text":"https://secwatch.observer/filing/0000950170-24-055657.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024055657/0000950170-24-055657-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024055657/om-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:42:31.208672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f32a2c5c058fbaa0be55e13257618dac04c4fcd","claim":"Outset Medical, Inc. reported first quarter ended March 31, 2024 results: net income $(39.9) million, EPS $(0.78) per share.","evidence_excerpt":"Revenue for the first quarter of 2024 was $28.2 million compared to $33.5 million in the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024055657/0000950170-24-055657-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$(39.9) million"},{"label":"EPS","value":"$(0.78) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"1f32a2c5c058fbaa0be55e13257618dac04c4fcd","claim":"Outset Medical, Inc. reported first quarter ended March 31, 2024 results: net income $(39.9) million, EPS $(0.78) per share.","evidence_excerpt":"Net loss was $(39.9) million, or $(0.78) per share, compared to net loss of $(44.0) million, or $(0.90) per share, for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024055657/0000950170-24-055657-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$(39.9) million"},{"label":"EPS","value":"$(0.78) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"260a44b67fd44ef05e96828582121ad7e65630d6","claim":"Outset Medical, Inc. reported full year 2024 results: revenue $145 million to $153 million. Guidance reaffirmed.","evidence_excerpt":"Outset reaffirmed its previously provided guidance for 2024 including revenue of $145 million to $153 million, growing 12% to 18% over 2023, and non-GAAP gross margin in the low-30% range for the full year 2024, exiting the year in the mid-30% range for the fourth quarter.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024055657/0000950170-24-055657-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"$145 million to $153 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"c7e7611994","claim":"Jean-Olivier Racine departed as Chief Technology Officer at Outset Medical, Inc..","evidence_excerpt":"Jean-Olivier Racine will depart from his role as the Company's Chief Technology Officer, effective May 17, 2024, in connection with the workforce reduction plan described in Item 8.01 below.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024055657/0000950170-24-055657-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}